Ad Hoc News (KC) 15-Apr-08
From Kidney Cancer Resource
To Go To Ad Hoc News (KC)
Preclinical data presented for Active Biotech's ANYARA technology
Lund, Sweden, April 15, 2008 - Active Biotech AB (OMX Nordic:ACTI) has presented results from pre-clinical studies at the 99th Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, USA.
Active Biotech AB (OMX Nordic:ACTI)has presented results from pre-clinical studies at the 99th AnnualMeeting of the American Association for Cancer Research (AACR) in SanDiego, USA.The technology behind the project ANYARA; Tumor TargetedSuperantigens; "TTS", was studied and evaluated in combination with astandard chemotherapeutic agent, Taxotere® (docetaxel).
The completeposter "Combining tumor-targeted superantigens with docetaxel resultsin synergistic anti-tumor effects in B16 tumor bearing mice" can beviewed at www.activebiotech.com.Combining TTS and Taxotere® significantly improved anti-tumoractivity compared to the respective mono therapy.
Furthermore,combining TTS and Taxotere® synergistically prolonged long-termsurvival in tumor bearing mice.In conclusion, the results of the study demonstrate that TTS therapyis suitable for combination treatment agents such as Taxotere®, andsuggest a significant potential for such a combination in humancancer therapy.The drug candidate ANYARA, using the TTS technology, is currently inpivotal Phase II/III clinical trials for Renal Cell Cancer and aninterim analysis is planned for mid 2008.ANYARA has also been tested in Phase I clinical trials with Taxotere®1) in patients with Non Small Cell Lung Cancer (NSCLC).
This trialdemonstrated that the combination is safe and indicated anti-tumoractivity.Lund April 15, 2008Active Biotech AB (publ)Sven AndréassonPresident and CEO1)Cohen RB, Borghaei H, Langer CJ, Alpaugh K, Lassen U, Afanasiev BV,Orlov SV, Yablonsky PK, Forsberg G, Hedlund G. An open label phase Istudy of ABR-217620 in combination with docetaxel in patients withNSCLC. In: AACR-NCI-EORTC International Conference on MolecularTargets and Cancer Therapeutics; 2007 Oct 22-26; San Francisco, CA.Philadelphia (PA): AACR; 2007.
Abstract nr A163.For further information, please contactSven Andréasson, President & CEO+46 (0)46 19 20 [email protected] Tomas Leanderson, Chief Scientific Officer+46 (0)46 19 20 [email protected] to editorsAbout ANYARAActive Biotech's ANYARA project develops a drug for use in cancertargeted therapy, primarily for the treatment of renal cell cancer.
APhase II/III study is ongoing since the end of 2006. It is arandomized study of ANYARA in combination with interferon-alpha,compared with only interferon-alpha, in patients with advanced renalcell cancer.The primary clinical effect parameter for this study is survival andit will include approximately 500 patients at 45 clinics in Europe.Expected survival with conventional treatment for these patients is10-15 months and the length of the study will depend on the patients'disease progression.
An interim analysis is scheduled for mid 2008.About Active BiotechActive Biotech AB (OMX Nordic:ACTI) is a biotechnology companyfocusing on research and development of pharmaceuticals. ActiveBiotech has a strong R&D portfolio with pipeline products focused onautoimmune/inflammatory diseases and cancer.
Most advanced projectsare laquinimod, an orally administered small molecule with uniqueimmunomodulatory properties for the treatment of multiple sclerosis,as well as ANYARA for use in cancer targeted therapy, primarily renalcancer. Further key projects in clinical development comprise thethree orally administered compounds TASQ for prostate cancer, 57-57for SLE and RhuDex® for RA.Active Biotech ABP.O. Box 724, SE-220 07 Lund, SwedenTel: +46 (0)46-19 20 00Fax: +46 (0)46-19 20 50.
To view the original article Click Here
Disclaimer
Kidney Cancer Resource (KCR) is not influenced by sponsors. The information contained herein is not intended as a substitute for the advice of an appropriately qualified and licensed physician or other licensed health care provider. The information provided here is for educational and information purposes only. Early accurate Diagnosis (Dx.) saves lives. Please check with a physician if you suspect you are ill, never ignore Symptoms. To help your health care specialist make an accurate Diagnosis please keep notes of dates, times and details of your Symptoms. We are not offering medical advice nor do we consider links, individuals or articles accessed through this site to be offering medical advice.
E&OE - Errors & Omissions Excepted
As much of the information posted on this Web Site for peoples convenience is of a medical or technical nature, and may be a matter of life or death the E&OE is a Disclaimer showing that to the best of our ability information is accurate and correctly written or transcribed. Before acting on information on this site you are responsible for checking it with your relevant medical team. We can not be held responsible for any Errors & Omissions made; nor for information on links and articles provided in good faith.
